Searchable abstracts of presentations at key conferences in endocrinology

ea0050p034 | Adrenal and Steroids | SFEBES2017

Management of ectopic ACTH syndrome: The birmingham experience

Hassan-Smith Zaki , May Christine , Shipman Kate , Boelaert Kristien , Ayuk John

Introduction: Ectopic ACTH syndrome (EAS) is a rare condition, accounting for approximately 10% of all Cushing’s syndrome (CS). We assessed the experience managing this condition in our centre.Methods: 171 patients (105 female, 66 male) with elevated plasma ACTH concentrations were identified from local IT systems at a tertiary centre (University Hospitals Birmingham NHS Foundation Trust) between 2002 and 2015. An electron...

ea0050p050 | Bone and Calcium | SFEBES2017

Discontinuation of denosumab–real world experience from a single centre

Venkataraman Hema , Dar Shuja , Hiwot Tarek , Criseno Sherwin , Hassan-Smith Zaki , Gittoes Neil

There is concern about rapid reduction in bone mineral density (BMD) and early rebound vertebral fractures following discontinuation of denosumab. Our aim was to review local experience of discontinuation of denosumab, changes in BMD and fractures in patients with osteoporosis.Methods: A retrospective analysis was conducted for patients who discontinued denosumab between March 2011 & June 2016. Denosumab withdrawal(DW) was defi...

ea0050p351 | Reproduction | SFEBES2017

Mass spectrometry-based assessment of androgen excess in 1205 consecutive patients over 5 years: PCOS most common diagnosis, but severe androgen excess indicates other ovarian and adrenal pathology

Elhassan Yasir , Idkowiak Jan , Smith Karen , Asia Miriam , Webster Rachel , Arlt Wiebke , O'Reilly Michael

Androgen excess in women is most commonly caused by polycystic ovary syndrome (PCOS), but sinister ovarian and adrenal pathology requiring immediate action needs to be excluded. Here we examined whether the severity of androgen excess indicates the likely underlying pathology in women evaluated for androgen excess.We included all women undergoing assessment of serum DHEAS, androstenedione (D4) and testosterone (T) by liquid chromatogra...

ea0050ep022 | Adrenal and Steroids | SFEBES2017

When One Diagnosis Reveals Another...

Heggie Alison , Nichols Matthew , Simkiss Lauri , Smith Jim , Nayar Rahul , Joshi Ashwin

A 37 year-old gentleman presented following an episode of dizziness while at work operating a fork-lift truck. There was no collapse or associated symptoms. He had been diagnosed with autoimmune hypothyroidism two months previously; commenced levothyroxine, currently at a dose of 75 micrograms daily; and lost ten kilograms in weight. On examination there were no signs of hypoadrenalism aside from a significant postural drop in blood pressure (lying 1...

ea0050p034 | Adrenal and Steroids | SFEBES2017

Management of ectopic ACTH syndrome: The birmingham experience

Hassan-Smith Zaki , May Christine , Shipman Kate , Boelaert Kristien , Ayuk John

Introduction: Ectopic ACTH syndrome (EAS) is a rare condition, accounting for approximately 10% of all Cushing’s syndrome (CS). We assessed the experience managing this condition in our centre.Methods: 171 patients (105 female, 66 male) with elevated plasma ACTH concentrations were identified from local IT systems at a tertiary centre (University Hospitals Birmingham NHS Foundation Trust) between 2002 and 2015. An electron...

ea0050p050 | Bone and Calcium | SFEBES2017

Discontinuation of denosumab–real world experience from a single centre

Venkataraman Hema , Dar Shuja , Hiwot Tarek , Criseno Sherwin , Hassan-Smith Zaki , Gittoes Neil

There is concern about rapid reduction in bone mineral density (BMD) and early rebound vertebral fractures following discontinuation of denosumab. Our aim was to review local experience of discontinuation of denosumab, changes in BMD and fractures in patients with osteoporosis.Methods: A retrospective analysis was conducted for patients who discontinued denosumab between March 2011 & June 2016. Denosumab withdrawal(DW) was defi...

ea0050p351 | Reproduction | SFEBES2017

Mass spectrometry-based assessment of androgen excess in 1205 consecutive patients over 5 years: PCOS most common diagnosis, but severe androgen excess indicates other ovarian and adrenal pathology

Elhassan Yasir , Idkowiak Jan , Smith Karen , Asia Miriam , Webster Rachel , Arlt Wiebke , O'Reilly Michael

Androgen excess in women is most commonly caused by polycystic ovary syndrome (PCOS), but sinister ovarian and adrenal pathology requiring immediate action needs to be excluded. Here we examined whether the severity of androgen excess indicates the likely underlying pathology in women evaluated for androgen excess.We included all women undergoing assessment of serum DHEAS, androstenedione (D4) and testosterone (T) by liquid chromatogra...

ea0050ep022 | Adrenal and Steroids | SFEBES2017

When One Diagnosis Reveals Another...

Heggie Alison , Nichols Matthew , Simkiss Lauri , Smith Jim , Nayar Rahul , Joshi Ashwin

A 37 year-old gentleman presented following an episode of dizziness while at work operating a fork-lift truck. There was no collapse or associated symptoms. He had been diagnosed with autoimmune hypothyroidism two months previously; commenced levothyroxine, currently at a dose of 75 micrograms daily; and lost ten kilograms in weight. On examination there were no signs of hypoadrenalism aside from a significant postural drop in blood pressure (lying 1...

ea0084op-04-21 | Oral Session 4: Basic 1 | ETA2022

CRYO-electron microscopy structures of human thyroid peroxidase (TPO) in complex with tpo antibodies

Baker Stuart , Nunez Miguel Ricardo , Thomas Daniel , Powell Michael , Furmaniak Jadwiga , Rees Smith Bernard

Objectives: Thyroid peroxidase (TPO) is a key enzyme in the synthesis of thyroid hormones and is a target for autoimmune responses in autoimmune thyroid disease. TPO autoantibody (TPOAb) binding epitopes have been mapped on the peroxidase domain (POD) and the complement control protein like domain (CCP). This study aimed to solve the molecular structures of TPO bound to TPO antibodies.Methods: An extracellular domain (ECD) of human TPO (amino acids; aa 1...

ea0084ps3-12-109 | Graves’ Disease 2 and Orbitopathy | ETA2022

Blocking the TSH receptor with human monoclonal autoantibody K1-70TM in patients with graves’ disease – results from a phase 1 clinical trial

Furmaniak Jadwiga , Sanders Jane , Sanders Paul , Li Yang , Rees Smith Bernard

Objectives: TSH receptor (TSHR) autoantibodies (TRAb) which mimic the actions of TSH are responsible for hyperthyroidism in Graves’ disease (GD) which is often associated with Graves’ orbitopathy (GO). K1-70 is a TSHR specific human monoclonal autoantibody which binds to the TSHR with high affinity and prevents stimulation of the TSHR by TSH and TRAb. Safety, tolerability, pharmacokinetic, pharmocodynamic and immunogenic effects of K1-70 in patients with GD were asse...